HR Positive Clinical Trials

11 recruitingLast updated: June 17, 2026

There are 11 actively recruiting hr positive clinical trials across 6 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3. Top locations include Tampa, Florida, United States, Birmingham, Alabama, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


HR Positive Trials at a Glance

11 actively recruiting trials for hr positive are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Tampa, Birmingham, and Houston. Lead sponsors running hr positive studies include First Affiliated Hospital of Zhejiang University, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, and Cogent Biosciences, Inc..

Browse hr positive trials by phase

Treatments under study

About HR Positive Clinical Trials

Looking for clinical trials for HR Positive? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HR Positive trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HR Positive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

Breast CancerTNBC - Triple-Negative Breast CancerEarly Stage Breast Cancer+2 more
Tempus AI900 enrolled14 locationsNCT07211178
Recruiting
Phase 1

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Endometrial CancerHER2-low Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Cogent Biosciences, Inc.90 enrolled2 locationsNCT07383506
Recruiting
Phase 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Metastatic Breast CancerAdvanced Breast CancerMetastatic Lung Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)392 enrolled36 locationsNCT06625775
Recruiting
Phase 2

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

HR Positive/HER2 Low Breast Cancer
First Affiliated Hospital of Zhejiang University111 enrolled5 locationsNCT07383818
Recruiting
Phase 2

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

HR Positive HER2 Negative Advanced Breast Cancer
wanghaibo120 enrolled2 locationsNCT07285382
Recruiting
Phase 1Phase 2

Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors

HR Positive HER2 Negative Advanced Breast Cancer
TYK Medicines, Inc180 enrolled2 locationsNCT06950086
Recruiting
Phase 1

PRE-I-SPY Phase I/Ib Oncology Platform Program

Triple-Negative Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+18 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226
Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Breast CancerBreast Cancer MetastaticBreast Carcinoma+37 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano3,500 enrolled24 locationsNCT06805812
Recruiting
Phase 2

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

HR Positive/HER2 Low Breast Cancer
Shengjing Hospital93 enrolled1 locationNCT06340230
Recruiting
Phase 3

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

HR Positive/HER2 Low Expression Metastatic Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University288 enrolled3 locationsNCT05904964
Recruiting
Not Applicable

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

HR Positive HER2 Negative Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital60 enrolled1 locationNCT05890287